Trial Profile
A pilot phase II study of PHA-739358 in patients with chronic myeloid leukemia relapsing on Gleevec [imatinib] or c-ABL therapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Danusertib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 14 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Oct 2006 New trial record.